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Abstract
A simple and versatile procedure has been developed for the determination of selenium in biological samples for clini-
cal purposes. The procedure consists of microwave sample digestion and the determination of selenium using atomic
fluorescence spectrometry with a hydride generation system (HG-AFS). The method allows the determination of sele-
nium in a range of 0.5–100.0 μg L–1 with a detection limit not higher than 0.2 μg L–1 and with good repeatability not ex-
ceeding 1%. It was applied for determination of selenium in women’s plasma samples (n = 90) with a suspicion of a thy-
roid cancer and the control group of women (n = 87). Most of the obtained results were in the range 30.0–60.0 μg L–1
and either did not match the physiological level of selenium in human plasma or indicate moderate selenium deficien-
cy. In the further examinations the thyroid tissues taken from 30 patients were analyzed. In most of the cases the sele-
nium concentration was found to be lower (0.14–1.67 μg g–1 wet weight) than its physiological level in a healthy tissue.
On this basis the hypothesis has been drawn that selenium can be considered as an additional marker of the thyroid can-
cer disease.
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1. Introduction
Food is the main source of easily available selenium
for living organisms. Concentration of selenium in plants de-
pends on the amount of this element present in the soil and
water, as well as on the level of environmental pollution.1
Epidemiologic investigations showed that the fre-
quency of tumor occurrence were significantly higher in
the regions typified by low selenium concentration in soil
than the others.2 Too low concentration of selenium in hu-
man tissues increases the risk of cancer but probably does
not have any influence on the size and the localization of
pathological changes.3,4 The examination carried out with
many patients proved that in some cases of cancer (e.g.
lung, breast, or prostate cancer) high selenium intake re-
duces morbidity and mortality caused by this disease.5–8
Similarly, it was found that 200 μg of selenium supple-
mented daily from yeast for four years or more led to sig-
nificant reduction (more than 60%) in case of prostate,
skin, and colorectal cancers.9,10 Moreover, Sundaram et al.
who studied the malignant neoplasm of the brain stated
that selenium was able to inhibit the growth of the tumor
cells causing their apoptosis. Authors suggested that sele-
nium or non-toxic selenium compounds could be some of
the most important prevention agents in the case of brain
tumor.11
It was found that in the malignant neoplasm of
breast or lung the selenium concentration was 1.7 times
higher comparing to healthy adjacent tissues. Although
the mechanism of selenium accumulation in tumor tissue
is still not well recognized, it is known that this effect is
connected with the process of induction of synthesis of
GSH-Px (glutathione peroxidase enzyme), which contains
selenium in its active center. This enzyme is one of the
primary antioxidants hence it prevents various pathologi-
cal changes in internal organs.12
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On the other hand, the research carried out in Kes-
han region, China (where the selenium intake is lowest
over the world) showed the inverse correlation between
the selenium concentration in blood and the incidence of
the cancer disease of lung, stomach, esophagus and li-
ver.13 In another research it has been stated that the con-
centration of selenium in body fluids of patients with tu-
mors was lower in most cases, comparing to healthy per-
sons.1–5
The diverse changes of selenium concentration
mentioned above could be connected with specific proper-
ties of selenium. This element is considered to be the
šmost toxic among essential elements’ as the difference
between its therapeutic and toxic level is very small.14
This is the reason for which the appropriate assessment of
the role of selenium in human organism requires an analy-
tical tool. It should be capable of determining this element
in tissues with especially good reliability in terms of accu-
racy and precision. As the concentration of selenium in
tissues is very low15–18 (see Table 1), the analytical techni-
que applied has to be also characterized by high sensiti-
vity and a low limit of detection. Nowadays a lot of analy-
tical methods are used to determination of selenium and
its speciation.19–25 Furthermore, due to the complexity of
the matrix of biological samples the calibration strategy
should be carefully taken into account.26
Accuracy of selenium determination in biological
samples mostly depends on the efficiency of its transfer
from an organic matrix to solution. Currently, the most
popular method of decomposition of organic matrix is mi-
crowave digestion27 (see Table 2). However, the described
procedures usually require the use of many reagents and
to apply multistage digestion processes in order to elimi-
nate interferences. As a consequence, they become expen-
sive and laborious. In addition, they provide many sources
of both random and systematic errors connected with pos-
sible contamination of reagents and/or a loss of an analyte
at each individual procedural stage.
Organs Physiological amount of selenium μg g
–1
Poland Germany Italy Bulgaria
Liver 0.54 0.29 1.60 0.82
Spleen 0.34 0.23 0.90 0.78
Kidney 0.61 1.09 0.77 4.78
Lung 0.15 0.13 1.16 *
Brain 0.13 0.11 * *
Heart * 0.28 * 0.63
Pancreas 0.30 * * *
Testicles * 0.30 * *
* no data available
Table 1. The average content in tissues in the different organs for
various populations.15–18
Table 2. Specification of digestion mixtures used for decomposition of various biological samples.27
* samples of reference materials,   ** digestion was made in the
open system.
No. Biological Required reagents Analyte Methods 
samples of analysis
1. bovine liver*,  HNO3-HClO4 
** As, Co, Cr, Cu, AAS, NAA
hair, nails Ni, Pb, Se, Zn
2. serum*, bovine liver HNO3-H2SO3, next H2O2 As, Se HG-AAS
3. pork liver HNO3-H2O2 Fe, Mn, Se F-AAS, HG-AFS
4. animals muscle*, HNO3 with add. 9 ppm Y As, Ba, Fe, K, PIXE
food samples* (internal standard) Mo, Ni, Pb, Se, Sr, V, Zn 
5. bovine liver*, food HNO3-HCl, next H2O2 B, Ba, Hg, Mn, ICP-AES,
samples*, sediment Ni, Pb, Sb, Se ET-AAS
6. blood*, urine*, HNO3-HClO4- H2SO3 As, Cd, Co, Cu, HG-AAS, 
bovine liver and muscle* Ni, Se,Pb DPASV
7. oyster tissue*, HNO3, next H2O2 Al, As, Ba, Ca, ICP-MS
human and animals muscles* Cd, Mg, Mn, Ni, Rb, 
Se, Sr i inne
8. pork kidney*, HNO3 Ag, Cd, Cu, Fe, ZE-ET-AAS, 
bovine liver* Ga, Hg, Mn, Pb, Sb, Se ET-AAS, FANES
9. crabs* (1) HNO3-HClO4 As, Cd, Co, Cr, ET-AAS, ICP-AES,
(2) HNO3-HClO4- HF Cu, Fe, Mn, Ni, Pb, Se F-AAS, ICP-MS, ASV
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The purpose of this work is to present a simple, fast
and inexpensive analytical procedure dedicated to the de-
termination of selenium in biological samples. Reliability
of the method has been verified by analyzing the referen-
ce materials of several biological materials. The method
was applied to the determination of selenium in women’s
plasma with thyroid disorders. Based on the results obtai-
ned the attempt was made to estimate the relation between
the occurrence of thyroid tumors and selenium concentra-
tion in this organ.
2. Experimental
2. 1. Reagents and Samples
Standard stock solutions containing 1000 mg L–1 Se
was prepared from Titrisol standards (Merck, Germany).
The working solutions were made with the use of concen-
trated HNO3 (Merck, Germany), concentrated HCl 
(POCh, Poland) and 98% (m/v) NaBH4 (Sigma-Aldrich
Chemise, Germany), 0.5% (m/v) NaOH (Sigma-Aldrich
Chemise, Germany). All reagents were of analytical rea-
gent grade. Doubly deionised water (< 1.0 μS cm–1) was
use throughout.
The following reference materials were examined:
human blood (LOT 404109, level 3, Norway), human se-
rum (MI01181, level 1, Norway), bovine liver (SRM
1577b, Germany) pig kidney (BCR 186, Belgium), pork
muscle (GBW 08552, China)
Plasma samples were obtained from the Blood Bank
in Krakow. Samples were taken from persons of good
health and not taking a selenium supplement. Plasma
samples and extracts of pathogenic thyroid tissues (the
study group) were obtained from patients with thyroid tu-
mors, from The Third Department of General Surgery,
Collegium Medicum in Krakow. The plasma and thyroid
tissue samples were stored frozen in polypropylene bott-
les at –20 °C until analysis.
2. 2. Instrumentation
The microwave system MARS X (CEM, Matthews,
USA) was used for sample digestion. An internal control
system allowed programmable control of the pressure and
temperature up to 5520 kPa (800 psi) and 220 °C, respec-
tively. The specific parameters of the digestion process
were given in Table 3. To remove gas from above digested
sample with the nitrogen stream, the Mini-vap device was
used (Sigma Aldrich, Germany).
A double-channel atomic fluorescence spectrometer
AFS-230 (Beijing Haiguang Instrument Co., China),
equipped with a 130-positional autosampler and a flow
hydride-generation system with an intermittent flow met-
hod, was used for the measurement of analytical signals.
The light sources used were cathode lamps (Se-HCL),
specially dedicated for AFS measurements. Operating
current (pulsed value) of these lamps was 100 mA. Argon
was used as the shield and the carrier gas with a flow of
800 and 500 mL min–1 respectively. The atomization pro-
cess occurred in the Ar–H2 flame at the temperature of
200 °C. The signals were measured for selenium and pro-
cessed in the peak area mode with the use of the IBM 586
computer.
Statistical calculations were carried out using the
commercially available package Statistica v. 6.0. (Stat-
Soft, Polska).
3. Results and Discussion
3. 1. Sample Preparation
Samples were digested according to the procedure
developed in our laboratory.28,29 Not more than 0.5 ml
(body fluid) or 0.5 g (solid tissue) of sample was placed in
a high-pressure teflon vessel, 7 mL of concentrated HNO3
was added and then the vessel was closed and transferred
into the microwave oven for digestion. The program of
mineralization was described in details in Table 3. After
digestion the vessel was cooled to the temperature of 25
°C. Then it was opened and the gas above the sample was
removed (see below for details) by a stream of nitrogen
gently flowing for several minutes. Then the sample was
transferred into a 25 mL volumetric flask, and 12.5 mL of
6 mol L–1 hydrochloric acid (as the pre-reduction reagent)
was added and the solution was diluted to the mark with
water.
Before introducing the solution into the AFS instru-
ment it was merged with a solution containing 2% (m v–1)
sodiumtetrahydroborate and 0.5% (m v–1) sodium hydro-
xide in the flow hydride generation system. Hydrochloric
acid in a concentration of 3 mol L–1 was used as a carrier
solution.
Three portions of each sample were digested at the
same time. Together with these, the blank (i.e. the solution
containing all the required reagents except sample) was
digested and then treated like a sample. Fluorescence for
selenium was measured as the difference between the sig-
nals produced by the sample and by the blank.
Table 3. Parameters of the optimized digestion procedure. 
Stage Power Temperature Pressure Ramp time Hold time 
% °C psi min. min.
I 90 180
II 90 200 350 4.00 4.00
III 95 220
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3. 2. Analytical Aspects
The serious problem dealing with the determination
of selenium in the form of hydrides is a strong negative
influence of nitrogen oxides on the analytical results.30,31
The cause of this effect was reported to be based on the
fact that nitrogen oxides prevent the reduction of analyte
ions to a compound that is capable of forming hydrides
with the highest efficiency. In order to avoid this effect it
is recommended to use a way that was proved to be effi-
cient in analyses of other biological materials:28,29,32 to re-
move nitrogen oxides from the mineralized sample using
the stream of an inert gas (argon, nitrogen) at pressure of 5
bar for a few minutes. The results shown in Table 4 revea-
led that selenium can be determined in various reference
materials with good accuracy and precision when nitrogen
is used for 10 minutes.
The analytical range was found to be linear up to100
μg L–1. The calibration can be performed with use of inor-
ganic standard solutions without their prior digestion or
other special treatment before measurements. The limit of
selenium detection in the biological samples examined
was defined to be 0.2 μg L–1.
confirm that thesis by means of the analytical method de-
veloped.
First, the analytical procedure was used to determine
selenium in the first group of women at risk of thyroid can-
cers. The 90 plasma samples were analyzed. All samples
were collected from patients before eating. In the same ti-
me and using the same conditions 87 samples of plasma ta-
ken from the other group of healthy women (the control
group) were analyzed. As the samples’ volumes were
small, each of them was analyzed only once. The results of
these experiments are shown in the Fig. 1. In addition, the
average physiological level of selenium determined on the
basis of literature data is also shown in Figure 1.37
Figure 1. Selenium level in plasma samples collected from women
with suspicion of cancer (hatched columns) and the control group
of women (empty columns). The roman numbers present the
groups of patients with different ranges of selenium level.
The results obtained for the whole study group were
assigned to subgroups of patients (from I to VII). Each
subgroup was characterized by a particular range of sele-
nium concentration in plasma. The majority of the obtai-
ned results did not match the physiological level of sele-
nium in human plasma. Only in 10 cases in 90 (group
IV–VII) the patients had normal amount of selenium. In
the remaining groups of patients the selenium status was
detected to be very low (I–III, 89% of all patients). In ad-
dition, the selenium level determined in 24% of patients
(group I–III) was so low as 30–40 μg L–1.
Further tests were concerning the determination of
selenium in thyroid gland tumors. According to available
data the pathology of the thyroid may be associated with io-
dine and also selenium deficiency.33,36 Therefore, many re-
search institutes decided to determine selenium concentra-
tion in blood or plasma and, at the same time in thyroid tis-
sues of patients with various thyroid diseases: nodular goi-
ter, thyroid cancer and Grave’s diseases. Similar research
was carried out in the group of patients with hyperthyroi-
dism, cancer and thyroid adenoma. In all cases the selenium
level was lower than average and the lowest level was ob-
served in thyroid tissues taken from patients with cancer.37
* confidence interval was calculated according to formula: Δx =
t(α,f)s/√n where α = 0.05, f = 2, n = 3 and s is the standard
deviation 
Materials Expelling 
Concentration of Se μg g–1
time min. Certified Found
Blood 0 79 ± 1.5 64.5 ± 5.5 *
5 71.5 ± 5.1
10 81.5 ± 1.4
Serum 0 80 ± 2.5 69.5 ± 5.4
5 71.5 ± 4.1
10 79.5 ± 1.3
Pig kidney 0 10.3 ± 0.5 < DL
5 9.86 ± 0.01
10 9.94 ± 0.01
Pork muscle 0 0.49 ± 0.05 0.246 ± 0.006
5 0.446 ± 0.003
10 0.492 ± 0.002
Bovine liver 0 0.73 ± 0.06 0.532 ± 0.081
5 0.701 ± 0.012
10 0.721 ± 0.003
Table 4. Results of the determination of selenium in the reference
samples obtained in different conditions defined by the time of the
removal of nitrous oxides by using the nitrogen stream.
3. 3. Application: Selenium Status 
and Cancer Disease – Case Studies
As mentioned in the introduction, numerous clini-
cal and epidemiological studies proved that the level of
selenium in human body fluids and tissues affects the risk
of the occurrence of some cancers, especially thyroid
cancer, which is the most common endocrine cancer.33–36
The aim of this part of the research presented here was to
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Thyroid tissue samples in present work were taken
during surgical operations on 30 patients from Collegium
Medicum UJ, Krakow. In most cases amounts of tissues
were very small and were ranged from 0.07 to 0.5 grams.
The patients were diagnosed with: struna nodosa;
Graves’ disease or toxic nodular goitre; follicular or ma-
crofollicular adenoma; papillary carcinoma; lymphoma
maligant. The selenium concentration results ranged from
0.14 to 1.67 μg g–1 (wet weight). The results assigned into
the subgroups are shown in Figure 2. They show that in
most patients (90% of study group) the selenium concen-
tration was found in thyroid tissues to be lower than the
physiological level typical for healthy tissues (i.e, ca 1.24
μg g–1). Moreover, in 50% of patients selenium was deter-
mined in very low concentration (less than 0.4 μg g–1).
Figure 2. Number of patients and the range of selenium concentra-
tion.
Figure 3 illustrates the relation between selenium le-
vels in thyroid tissues and the types of diseases the pa-
tients were diagnosed with. Kruskal-Wallis test was ap-
plied in order to check for any differences between vari-
ous groups of patients and to find the possible relation bet-
ween selenium level and diagnosed diseases. Differences
with p < 0.05 were considered to be statistically signifi-
cant. The analysis did not reveal statistically significant
differences between studied groups (p = 0.374).
4. Conclusions
Interesting papers showing the influence of sele-
nium on human health encourage many authors to inten-
sify their study on the biological function of selenium and
its influence on the human body. Obtaining reliable infor-
mation on this subject, is in a large measure depending on
the selection and skilful application of proper analytical
methods.
In the presented study a simple and low cost method
was shown which gives a great possibility to determine
selenium with good accuracy and precision at the low se-
lenium levels (at physiological levels and lower) in vari-
ous biological materials. The reliability of this method
was successfully confirmed many times by analysis of a
great number of various reference materials.
It was proved that the presented method can be used
to determine selenium in the human tissues taken from
people suffering from cancer. The obtained results of pla-
sma samples and thyroid tissues show the association bet-
ween selenium level and a risk of cancer. Moreover, the re-
sults proved the hypothesis that a low selenium level is
characteristic for thyroid cancer and it can be a ,,marker”
of this kind of disease. The research also showed that in the
group of women with a risk of cancer the revealed plasma
selenium levels were significantly lower than physiologi-
cal level. However, it was not proved that there is any asso-
ciation between selenium concentrations in pathogenically
changed tissues taken from an examined group with types
of thyroid disease. It is possible that the correlation could
be proved on the basis of analytical examinations with par-
ticipation of much greater number of patients.
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Povzetek
Razvili smo enostaven postopek za dolo~anje selena v biolo{kih vzorcih. Vzorec razkrojimo s pomo~jo mikrovalov ter
nadaljujemo z dolo~itvijo selena s pomo~jo atomske fluorescen~ne spektrometrije s hidridno tehniko (HG-AFS). Meto-
da je uporabna v obmo~ju 0,5–100 g L–1 z mejo dolo~itve 0,2 g L–1 ter ponovljivostjo 1 %. Uporabili smo jo za dolo~a-
nje selena v krvni plazmi `ensk (n = 90), pri katerih smo sumili prisotnost tiroidnega raka, ter pri kontrolni skupini (n =
87). Ve~ina rezultatov je bila v obmo~ju 30–60 g L–1, kar ne odgovarja fiziolo{kim koncentracijam selena v ~love{ki
plazmi ali ka`e celo na pomanjkanje. V nadaljnjih raziskavah smo preverili {e tiroidna tkiva 30 pacientk in ugotovili zni-
`ane koncentracije (0,14–1,67 g g–1 mokre mase). Na osnovi tega smo zaklju~ili, da lahko selen uporabimo kot dodatni
marker za prisotnost tiroidnega raka.
